Lymphocyte development & homeostasis.
Lead Research Organisation:
Babraham Institute
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The intrinsic lifespan of lymphocyte subsets increases as the cells progress through the immature, naïve and memory stages. This represents a paradigm for the reprogramming of cell lifespan in vivo but the molecular basis for this is incompletely understood. For example, while naïve B and T cells may survive for months, memory B and T cells last for years, perhaps reflecting a greater potential for self-renewal [49]. Maintenance within the naïve pool is also dependent upon interclonal competition and memory cells are far less subject to this competition which may also contribute to their increased lifespan. The size of the pool of naive lymphocytes is limited by competition for trophic factors such as the TNF superfamily member BAFF (tnfsf13B) in the case of Marginal Zone (MZ) and Follicular (B2) B cell subsets and IL-7 in the case of T cells [50]. B1 B cells, by contrast, maintain self-renewal independently of BAFF and the factors that regulate the lifespan of certain epithelial T cell subsets remain unknown. These features of lymphocyte lifespan are linked to the extrinsic and intrinsic factors that dictate the upper limits of the number of lymphocytes at each developmental stage. This may be linked to specific signalling pathways that regulate organ size, e.g. the PI3K pathway. For instance, the number of marginal zone B cells is proportional to the activity of the PI3K pathway within B cells. The PI3K pathway in T cells determines the number of T-follicular helper cells and, in a non-cell autonomous manner, the number of germinal centre (GC) B cells. Our identification of genes and pathways that regulate lymphocyte development and survival now permits us to investigate mechanisms through which these pathways function and connect to other components of lymphocyte homeostasis (e.g. the Bcl2 pathway). In addition, we have found that TIS11b is necessary for the development and turnover of the B1 and MZ B cell pools. This finding not only confirms the need to uncover how signalling pathways regulate the transcriptional programmes affecting cell fate but also emphasise the profound effects that the control of mRNA stability and translational efficiency can impart. So far, three out of the 8 mouse GIMAP GTPases have been shown to influence lymphocyte survival, either positively (GIMAPs 1 and 5) or negatively (GIMAP4 – an accelerator of apoptosis) [7, 51-52]. Given their strong expression in resting lymphocytes, roles can be expected for the remaining family members shared across species, namely the cytosolic members GIMAP6, 8 and 7/9. We predict that, in common with most GTPases, the cell biological role of the GIMAPs will lie in the re-fashioning of parts of the lymphocytes’ intracellular membraneous organelles in response to developmental, homeostatic and activation requirements.
Planned Impact
unavailable
Organisations
- Babraham Institute (Lead Research Organisation)
- Francis Crick Institute (Collaboration)
- Cancer Research Technology (CRT) (Collaboration)
- University of Oxford (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- F-star Therapeutics (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Erasmus MC (Collaboration)
Publications
Abdelrasoul H
(2018)
PI3K induces B-cell development and regulates B cell identity.
in Scientific reports
Afzali B
(2017)
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.
in Nature immunology
Afzali B
(2017)
BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.
in Nature immunology
Aloulou M
(2016)
Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells.
in Nature communications
Alvisi G
(2023)
High-Dimensional Single-Cell Profiling of Tumor-Infiltrating CD4+ Regulatory T Cells.
in Methods in molecular biology (Clifton, N.J.)
Alvisi G
(2020)
IRF4 instructs effector Treg differentiation and immune suppression in human cancer.
in The Journal of clinical investigation
Barros-Martins J
(2016)
Effector ?d T Cell Differentiation Relies on Master but Not Auxiliary Th Cell Transcription Factors.
in Journal of immunology (Baltimore, Md. : 1950)
Bignon A
(2017)
Escherichia coli Heat-Labile Enterotoxin B Limits T Cells Activation by Promoting Immature Dendritic Cells and Enhancing Regulatory T Cell Function.
in Frontiers in immunology
Browning MJ
(2015)
Cowden's syndrome with immunodeficiency.
in Journal of medical genetics
| Title | PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS |
| Description | Peripheral nervous system (PNS) neurons support axon regeneration into adulthood, whereas central nervous system (CNS) neurons lose regenerative ability after development. To better understand this decline whilst aiming to improve regeneration, we focused on phosphoinositide 3-kinase (PI3K) and its product phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We demonstrate that adult PNS neurons utilise two catalytic subunits of PI3K for axon regeneration: p110a and p110d. However, in the CNS, axonal PIP3 decreases with development at the time when axon transport declines and regenerative competence is lost. Overexpressing p110a in CNS neurons had no effect; however, expression of p110d restored axonal PIP3 and increased regenerative axon transport. p110d expression enhanced CNS regeneration in both rat and human neurons and in transgenic mice, functioning in the same way as the hyperactivating H1047R mutation of p110a. Furthermore, viral delivery of p110d promoted robust regeneration after optic nerve injury. These findings establish a deficit of axonal PIP3 as a key reason for intrinsic regeneration failure and demonstrate that native p110d facilitates axon regeneration by functioning in a hyperactive fashion. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| URL | https://axonrepair2020.figshare.com/articles/poster/PI_3-kinase_delta_enhances_axonal_PIP3_to_suppor... |
| Title | PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS |
| Description | Peripheral nervous system (PNS) neurons support axon regeneration into adulthood, whereas central nervous system (CNS) neurons lose regenerative ability after development. To better understand this decline whilst aiming to improve regeneration, we focused on phosphoinositide 3-kinase (PI3K) and its product phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We demonstrate that adult PNS neurons utilise two catalytic subunits of PI3K for axon regeneration: p110a and p110d. However, in the CNS, axonal PIP3 decreases with development at the time when axon transport declines and regenerative competence is lost. Overexpressing p110a in CNS neurons had no effect; however, expression of p110d restored axonal PIP3 and increased regenerative axon transport. p110d expression enhanced CNS regeneration in both rat and human neurons and in transgenic mice, functioning in the same way as the hyperactivating H1047R mutation of p110a. Furthermore, viral delivery of p110d promoted robust regeneration after optic nerve injury. These findings establish a deficit of axonal PIP3 as a key reason for intrinsic regeneration failure and demonstrate that native p110d facilitates axon regeneration by functioning in a hyperactive fashion. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2020 |
| URL | https://axonrepair2020.figshare.com/articles/poster/PI_3-kinase_delta_enhances_axonal_PIP3_to_suppor... |
| Description | Our studies on lymphocyte development and homeostasis discovered new roles for a family of poorly characterised gene in T and B cell homeostasis. It now turns out that these genes the GIMAPs are linked to human immunodeficiency and our expertise and research tools are accelerating the discovery of the nature of this immunodeficiency. Work on PI3K extended our understanding of its role in the survival of lymphocytes in normal and pathological situations; this helps understand how and when use of small molecule inhibitors of P110delta in B cell malignancy (this builds on a long-term investment BBSRC made in our science. We also found P110delta was importation regulatory T cells where its absence undermined their function; an observation that may explain its efficacy in some tumours, but also explain its unwanted side effects. Work on RNA binding proteins broke new ground on the mechanisms of lymphocyte development and activation. We discovered that they were fundamental for regulating quiescence a finding that has implications for many cells outside of the immune system. It also has implications for malignancy and it is becoming increasingly evident that we have discovered a new class of tumour suppressors. This was not an expected result at the outset. We also completed and published studies of the role of epithelial lymphocytes which are important for maintain tissue homeostasis at barrier surfaces. We discovered that stress responses were instructive in lymphocyte cell fate decisions. Overall, we discovered fundamental new knowledge about lymphocyte development and homeostasis. This has implications for biology of ageing-for the formation of the immune system and how it turns against our own bodies as we age. This thinking has underpinned new approaches towards understanding how lymphocytes contribute to the infection-free inflammatory "disease" that occurs as we age. Our discoveries have led to significant new funding and recognition including industrial funding. Of note work is being taken forward in new projects such as that funded by the Global Challenges Research Fund. Other work has attracted Industry attention and we are part of a research alliance with CRT funded by Celgene. Based on our work on B cells we have also become part of a H2020-MCSA Innovative Training Network. |
| Exploitation Route | see the above answer |
| Sectors | Healthcare |
| Description | work on Pi3k has underpinned drug discovery and led to treatment of CLL and lymphoma.the work on RNA binding proteins is leading to new insights into development and function of the immune system. This is having impact e.g. see http://commercial.cancerresearchuk.org/cancer-research-uk-announces-drug-discovery-collaboration-celgene-corporation |
| First Year Of Impact | 2015 |
| Sector | Healthcare |
| Description | Gilead Oncology Faculty |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Following the EMA approval of Zydelig® (idelalisib) in September 2014, and the presentation of new data on idelalisib at ASH 2014, Gilead medical affairs launched a new idelalisib speaker programme, known as "Gilead Oncology Faculty". This medically led, non-promotional activity aims to provide engaged experts the opportunity to be trained on idelalisib data of high quality and scientific content (on label; new indications and new oncology drugs within the Gilead portfolio to be added according to their approval) and subsequently, to give Gilead affiliates across the EMEA region engagement opportunities with registered haematology experts for their local / regional non-promotional speaking events. |
| URL | https://www.gileadfaculty.com |
| Description | Wellcome science Interview committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://wellcome.org/grant-funding/guidance/funding-application-advisory-committees/science-intervie... |
| Description | BBSRC GCRF Data & Resources |
| Amount | £171,733 (GBP) |
| Funding ID | BBS/OS/GC/000008A |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 07/2017 |
| Description | Celgen CRT Translation Alliance |
| Amount | £500,000 (GBP) |
| Organisation | Cancer Research Technology (CRT) |
| Sector | Private |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | EMBO Young Investigator Award |
| Amount | € 25,000 (EUR) |
| Organisation | European Molecular Biology Organisation |
| Sector | Charity/Non Profit |
| Country | Germany |
| Start | 01/2017 |
| End | 12/2020 |
| Description | ERC starting grant |
| Amount | € 1,500,000 (EUR) |
| Funding ID | LS6_637801 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 05/2015 |
| End | 05/2020 |
| Description | GCRF Networks in Vaccines Research and Development |
| Amount | £1,000,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 10/2022 |
| Description | High-throughput automation of sequencing library generation for Wellcome Trust-funded research at the Babraham Institute |
| Amount | £244,089 (GBP) |
| Funding ID | 208380/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 01/2019 |
| Description | ITN |
| Amount | € 36,052,456 (EUR) |
| Funding ID | COSMIC |
| Organisation | European Commission |
| Department | Horizon 2020 |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2018 |
| End | 12/2022 |
| Description | Initial Training Networks (ITN): Horizon 2020 |
| Amount | € 6,000,000 (EUR) |
| Funding ID | ENLIGHT-TEN - AMD-675395-1 |
| Organisation | European Commission |
| Department | Horizon 2020 |
| Sector | Public |
| Country | European Union (EU) |
| Start | 09/2015 |
| End | 09/2019 |
| Description | Investigator Award |
| Amount | £1,300,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | Lost-Tfh) Lost in space: How spatial dysregulation of T follicular helper cells impairs vaccine responses in ageing |
| Amount | £1,723,611 (GBP) |
| Funding ID | EP/X022382/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 08/2027 |
| Description | Mechanisms of regulatory T Treg cell stability in health and disease |
| Amount | £96,696 (GBP) |
| Funding ID | BB/P504555/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 09/2020 |
| Description | Molecular regulation of NK cell functional maturation by the transcription factor BACH2 |
| Amount | £658,607 (GBP) |
| Funding ID | MR/S024468/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 05/2022 |
| Description | Resolving mechanisms of gene regulation within the immune system using forward genetics |
| Amount | £200,000 (GBP) |
| Organisation | Lister Institute of Preventive Medicine |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 10/2019 |
| Description | Small Molecule Drug Discovery Award |
| Amount | £300,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2020 |
| Title | Guidelines for the use of flow cytometry and cell sorting in immunological studies |
| Description | "Guidelines for the use of flow cytometry and cell sorting in immunological studies" represent a community effort to collect the currently accepted best methods for monitoring most of the variation of the major players of immune system (along with their organelles and functionality) and include standards for data interpretation, as well as cautions about technical issues. One aspect of the guidelines concerns data reproducibility, a topic that has recently attracted considerable attention. Therefore, the guidelines are meant to help researchers avoid potential pitfalls that could drastically alter the interpretation of their data. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | paper has been widely dowloaded, read and cited |
| URL | https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201646632 |
| Title | mouse model |
| Description | We have generated novel mouse models. The details of many of these are available in our peer-reviewed papers. A number of models are still under evaluation |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | see pubished papers |
| Title | plasmids and libraries |
| Description | plasmids and libraries. there are multiple entires on the resource |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | publications |
| URL | https://www.addgene.org/Martin_Turner/ |
| Description | Celgene CRT Alliance |
| Organisation | Cancer Research Technology (CRT) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Celgene CRT alliances been described here http://commercial.cancerresearchuk.org/cancer-research-uk-announces-drug-discovery-collaboration-celgene-corporation we are one of the academic partners |
| Collaborator Contribution | This is a complex collaboration involving MRC, BBSRC, Wellcome and CRUK funded groups |
| Impact | many, but specifically I have extended the contract of a talented postdoc in my lab. I would add that this is new money from Celgene which is a US company-so this is a genuine economic impact in the UK |
| Start Year | 2018 |
| Description | Collaboration with Jernej Use |
| Organisation | Francis Crick Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | shared expertise |
| Collaborator Contribution | shared expertise |
| Impact | https://www.biorxiv.org/content/10.1101/2021.08.27.457890v1 |
| Start Year | 2014 |
| Description | Depleting regulatory T (Treg) cells in cancer |
| Organisation | Cancer Research Technology (CRT) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have generated preliminary data that has formed the basis for a drug development programme aimed at generating new immune based therapies for cancer that work by depleting immunosuppressive regulatory T cells accumulating within tumours |
| Collaborator Contribution | A discussion is currently underway to undertake an industrial collaboration with CRUK-TDL |
| Impact | Not yet delivered |
| Start Year | 2018 |
| Description | Drug discovery programme targeting the immunosuppressive transcription factor activity of BACH2 |
| Organisation | Cancer Research Technology (CRT) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have previously found that BACH2 promotes tumour immunosuppression by promoting Foxp3+ Treg cell-mediated suppression of CD8+ T cells and IFN-? within tumors (Roychoudhuri et al., J Clin Invest. 2016). This has formed the basis for an on-campus industrial collaboration with Cancer Research Technology (CRT). We aim to develop a cell-based reporter assay for the transcription factor activity of BACH2 in order to perform a high-throughput screen of small molecule inhibitors. The collaboration resulted from a meeting arranged by Martin Turner between LLSD and CRT and was supported by a Babraham Institute Knowledge Exchange and Commercialisation Committee Campus Collaboration Award (£15K). Preliminary data generated formed the basis for a successful application for a CRUK Drug Discovery Award (£300K). We are developing stable reporter cell lines using bioinformatically derived enhancer sequences that are responsive to transcriptional repression by BACH2 and amenable to high-throughput drug screening by our collaborators at CRT. |
| Collaborator Contribution | Performance of a high-throughput drug screen (>200k compounds) using cell-based reporter assays for the transcription factor activity of BACH2 generated in the laboratory. |
| Impact | This collaboration resulted in receipt of further funding - a BI Knowledge Exchange and Commercialisation Committee Campus Collaboration Award (£15K) and a CRUK Drug Discovery Award (£300K) |
| Start Year | 2017 |
| Description | EM Studies of GIMAP GTPases |
| Organisation | University of Cambridge |
| Department | Cambridge Institute for Medical Research (CIMR) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of cellular materials and specific antibodies |
| Collaborator Contribution | Performance of electron microscopic analysis |
| Impact | Publication: PMID: 21487483 |
| Start Year | 2009 |
| Description | Human Gimap studies |
| Organisation | University of Oxford |
| Department | Weatherall Institute of Molecular Medicine (WIMM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Advice, reagents. |
| Collaborator Contribution | We have advised on ongoing studies of Gimap proteins in human immunology and mouse model systems. We have provided specific antibody reagents from our collection. |
| Impact | Progress but no outputs as yet. |
| Start Year | 2016 |
| Description | Katsikis new |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | exchange of reagents and knowhow |
| Collaborator Contribution | exchange of reagents and knowhow |
| Impact | non so far |
| Start Year | 2014 |
| Description | Transcriptional and epigenetic programmes of lung inflammation |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | A key commercial collaboration between Rahul Roychoudhuri (RR) and GlaxoSmithKline (GSK)/Epinova, which is now supported by two BBSRC CASE awards, aims to understand the transcriptional and epigenetic programmes that promote lung inflammation. We aim to define transcriptional and epigenetic mechanisms by which airway immune homeostasis is maintained by transcriptional and epigenetic regulators. |
| Collaborator Contribution | Support of CASE awards, co-supervision of PhD students, supply of pharmacological agents for use as tool compounds in assessment of epigenetic regulators |
| Impact | We have gained an understanding of how lung inflammation is restrained by suppression of ILC2 activation and promotion of Treg differentiation by the transcription factor BACH2 and are exploring mechanisms by which BACH2 may regulate epigenetic programmes in T cells |
| Start Year | 2016 |
| Description | Understanding the molecular and cellular basis for the function of agonist antibody-based immunotherapies |
| Organisation | F-star Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | This collaboration with F-Star Biotechnology Limited aims to understand the molecular and cellular basis for the function of agonist antibody-based immunotherapies in cancer. The work, funded by F-Star, will take place in our laboratory and will be undertaken by a funded postdoctoral scientist. The collaboration is facilitated by the proximity of the Institute to F-Star on the Babraham Research Campus |
| Collaborator Contribution | F-Star have fully funded the research collaboration and are providing reagents for the investigations which will be conducted using pre-clinical mouse models. |
| Impact | Immunology Molecular biology Drug development Bioinformatics |
| Start Year | 2019 |
| Description | BBC World service interview for Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Discussed the findings reported in our 2016 paper on ageing and the immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC radio 4 today programme interview for Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview on BBC radio 4 to discuss the findings reported in our 2016 paper on ageing and the immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC radio Cambridge interview for Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview to discuss our 2016 publication on Ageing and the Immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC radio Scotland interview for Carr et al (2016 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview with BBC radio scotland on our 2016 paper on ageing and the immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | Cambridge Bioresource volunteer event, CRUK, Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented our work on ageing and the response to vaccination to an adult lay audience. This included people who are interested in taking part in research studies. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Discussed animal research on Cambridge TV |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | I was interviewed for a programme aired on Cambridge TV about the use of animals in research. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.cambridge-tv.co.uk/impact-animal-research/ |
| Description | Interview for French radio for Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview to discuss the findings of our research on ageing and the immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | Interview for Swiss Radio (French) Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview to discuss the results reported in our 2016 paper on ageing and the immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | Interview with Cambridge TV for Carr et al (2016) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | An interview about our 2016 publication on ageing and the human immune system |
| Year(s) Of Engagement Activity | 2016 |
| Description | Interview with Naked Scientists for podcast (2015) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview with the Naked Scientists on our research into Ageing |
| Year(s) Of Engagement Activity | 2015 |
| Description | Invited speaker at NIH Workshop: Advances in Aging, Immunity, and Chronic Inflammatory Disease |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presented our work on ageing and vaccination to the NIH, NIA, NIAID and NIDCR Workshop: Advances in Aging, Immunity, and Chronic Inflammatory Disease |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.nia.nih.gov/research/dab/workshop-advances-aging-immunity-and-chronic-inflammatory-disea... |
| Description | Invited speaker: Sanofi Immune Memory Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Michelle Linterman was invited to present at a conference organised by Sanofi Pasteur at their headquarters in France. The presentation was followed by questions and discussion. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Participation in an activity, workshop or similar - School visit to the Roychoudhuri laboratory for hands-on experience in flow cytometry and cellular immunology |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | The laboratory hosted a group of 6 sixth form school students to undertake a flow cytometry experiment in cellular immunology with bench research, teaching from PhD and Postdocs in the group |
| Year(s) Of Engagement Activity | 2020 |
| Description | Policy Discussion with Rebecca Jones, Head of Cancer, Ageing and Digipath at Office for Life Sciences DHSC/BEIS, about ageing research in the UK |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Rebecca leads the Cancer, Ageing and Digipath team in the Office for Life Sciences taking a missions approach to tackling two of the greatest healthcare challenges facing society - Cancer and Ageing - working in partnership with stakeholders across HMG, NHS, academia, patient groups, industry and the third sector. Using developments in research and innovation, the missions will work to improve cancer diagnosis, treatment and care, and towards preventing people developing multiple long-term conditions as they age. Her team also leads an ongoing programme to digitise and use AI in pathology and imaging in the NHS. She is currently a policy fellow at CSaP (https://www.csap.cam.ac.uk/network/rebecca-jones/) we met to discuss ageing in the UK |
| Year(s) Of Engagement Activity | 2023 |
| Description | Policy discussion with Dr Adrian Baker, Research Lead in the Innovation, Research, and Life Sciences Group and the Accelerated Access Collaborative at NHS England |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Dr Baker and I discussed frameworks to facilitate participation in research by the public, and ways that this could be enhanced. We also discussed ways to facilitate the translation of basic research into interventions that have social and economic impact. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.csap.cam.ac.uk/network/adrian-baker-nhs/ |
| Description | Presentation at Glaxo Smith Kline, Stevenage, United Kingdom |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | Presentations from Michelle Linterman and Alice Denton on the basic biology of the response to vaccination, with a specific focus on the biology of stromal cells. The presentations were followed by a discussion. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Presentation on the use of mouse models in immunology research |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation of the reasons and uses of research using mouse models in immunology research to a large group of local parishioners visiting the Institute for the talk. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Public talk on Ageing and the immune system at the Cambridge Corn Exchange (2016) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A public presentation of our work on Ageing and the response to vaccination |
| Year(s) Of Engagement Activity | 2016 |
| Description | Royal Society Summer Exhibition, 2015: Immune Army |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | We presented our exhibition: "Immune Army: weapons of microscopic destruction"; at the Royal Society Summer exhibition 2015. Many members of my lab participated in the design of the exhibition materials, the accompanying video (https://youtu.be/oMj8UxMPYJU) and at the exhibition itself. I spent two full days at the exhibition. Work on Activated PI3K Delta Syndrome (APDS) and Cancer immunotherapy from my lab featured prominently in this exhibition. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://sse.royalsociety.org/2015/immune-army/ |
| Description | T.V. interview BBC look east 2017 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview on our research on how the response to vaccination changes with age |
| Year(s) Of Engagement Activity | 2016 |
| Description | Talk at GSK 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | A presentation was given at the Glaxo Smith Klein site in Stevenage, UK on our work on the germinal centre response. Following this visit a joint BBSRC iCASE award was made for a PhD student to be shared between the Babraham Institute and GSK. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Talk on ageing to local discussion group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | This was an evening talk to a local discussion group in Great Abington, Cambridgeshire delivered by G.B and Prof Joanna Latimer (University of York) who is a Public Engagement collaborator of the Institute. Our presentation covered both the biology of ageing (illustrated by examples of relevant Babraham science) and sociological aspects of our private and public attitudes to ageing. A wide-ranging and rich discussion took place with the audience of 15-20. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Visit of School Teachers in the lab 2016 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Discuss and demonstrate our research to visiting teachers in our laboratory. |
| Year(s) Of Engagement Activity | 2016 |
| Description | WMD |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | WMD: Weapons on microscopic destruction was a multimedia presentation by students postdocs and project leaders. it involved the use of iPADs, games and fridge magnets to engage discussion of how the immune system works and how it is affected by ageing. it has been presented multiple times and has engaged many young and older individuals |
| Year(s) Of Engagement Activity | 2014 |
| Description | open day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | practical demonstrations and participation in a simple experiment inspired young people |
| Year(s) Of Engagement Activity | 2006,2007,2008,2009,2010,2011,2012,2013,2014 |
